NCT06714591 - Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1 | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

December 19, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

March 30, 2027

Conditions

Relapsed/Refractory Acute Myeloid Leukemia

Interventions

DRUG

BL-M11D1

"The study includes 2 parts:~Part 1 Dose escalation and Dose Finding"

Trial Locations (14)

22031

RECRUITING

Virginia Cancer Specialists, Fairfax

24014

RECRUITING

Oncology & Hematology Associates of Southwest Virginia, Inc., Roanoke

24224

RECRUITING

WVCI Oncology Associates of Oregon, Eugene

33612

RECRUITING

Moffitt Cancer Center, Tampa

37203

RECRUITING

SCRI -TriStar BMT, Nashville

43210

RECRUITING

The Ohio State University Comprehensive Cancer Center, Columbus

45236

RECRUITING

Oncology Hematology Care Clinical Trials, LLC, Cincinnati

49546

RECRUITING

START Midwest/The Cancer and Hematology Center, Grand Rapids

77030

RECRUITING

MD Anderson Cancer Center, Houston

78240

RECRUITING

Texas Oncology, P.A., San Antonio

90095

RECRUITING

UCLA Ronald Reagan Medical Center, Los Angeles

91010

NOT_YET_RECRUITING

City of Hope, Duarte

98109

NOT_YET_RECRUITING

Fred Hutchinson Cancer Center, Seattle

06511

RECRUITING

Yale Cancer Center, Smilow Cancer Hospital at Yale New Haven, New Haven

All Listed Sponsors

lead

SystImmune Inc.

INDUSTRY